Jazz Pharmaceuticals (JAZZ) Tops Q3 EPS by 89c
Tweet
Share
E-mail
Get Alerts JAZZ Hot Sheet
Price: $246.91 -0.54%
EPS Growth %: +174.9%
Financial Fact:
Product sales, net: 371.62M
Today's EPS Names:
CCEL, SLP, TMQ, More
EPS Growth %: +174.9%
Financial Fact:
Product sales, net: 371.62M
Today's EPS Names:
CCEL, SLP, TMQ, More
Join SI Premium – FREE
Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q3 EPS of $4.20, $0.89 better than the analyst estimate of $3.31. Revenue for the quarter came in at $838.1 million versus the consensus estimate of $832.52 million.
For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Key things to know ahead of SK Hynix’s blockbuster US listing
- EquipmentShare raises 2026 outlook, approves $500M buyback
- Piper Sandler Reiterates Overweight Rating on Reddit (RDDT)
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
